

Etoricoxib Granulation Formulation

Version 3.6 Revision Date: 09.04.2021 SDS Number: 16722-00019 Date of last issue: 16.10.2020
Date of first issue: 29.09.2014

SECTION 1: Identification of the substance/mixture and of the company/undertaking**1.1 Product identifier**

Trade name : Etoricoxib Granulation Formulation
Product code : ETORICOXIB GRANULATION

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.
30 Hudson Street, 33rd floor
07302 Jersey City, New Jersey, U.S.A

Telephone : 551-430-6000

E-mail address of person responsible for the SDS : EHSSTEWARD@organon.com


1.4 Emergency telephone number

215-631-6999

SECTION 2: Hazards identification**2.1 Classification of the substance or mixture****Classification (REGULATION (EC) No 1272/2008)**

Reproductive toxicity, Category 2	H361d: Suspected of damaging the unborn child.
Specific target organ toxicity - repeated exposure, Category 2	H373: May cause damage to organs through prolonged or repeated exposure.
Long-term (chronic) aquatic hazard, Category 2	H411: Toxic to aquatic life with long lasting effects.

2.2 Label elements**Labelling (REGULATION (EC) No 1272/2008)**

Hazard pictograms :  

Signal word : Warning

Hazard statements : H361d Suspected of damaging the unborn child.
H373 May cause damage to organs through prolonged or repeated exposure.
H411 Toxic to aquatic life with long lasting effects.

Etoricoxib Granulation Formulation

Version 3.6 Revision Date: 09.04.2021 SDS Number: 16722-00019 Date of last issue: 16.10.2020
Date of first issue: 29.09.2014

Precautionary statements : **Prevention:**
 P201 Obtain special instructions before use.
 P260 Do not breathe dust.
 P273 Avoid release to the environment.
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
Response:
 P308 + P313 IF exposed or concerned: Get medical advice/ attention.
 P391 Collect spillage.

Hazardous components which must be listed on the label:
 Etoricoxib

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients**3.2 Mixtures****Components**

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Etoricoxib	202409-33-4	Acute Tox. 4; H302 Repr. 2; H361d STOT RE 2; H373 (Kidney, Liver, Gastrointestinal tract) Aquatic Chronic 2; H411	>= 25 - < 30

For explanation of abbreviations see section 16.

SECTION 4: First aid measures**4.1 Description of first aid measures**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
 When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Etoricoxib Granulation Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
3.6	09.04.2021	16722-00019	Date of first issue: 29.09.2014

- If inhaled : If inhaled, remove to fresh air.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

- Risks : Suspected of damaging the unborn child.
May cause damage to organs through prolonged or repeated exposure.
- Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures**5.1 Extinguishing media**

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

- Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
Metal oxides
Oxides of phosphorus
Nitrogen oxides (NO_x)

Etoricoxib Granulation Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
3.6	09.04.2021	16722-00019	Date of first issue: 29.09.2014

Sulphur oxides
Chlorine compounds

5.3 Advice for firefighters

- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
-

SECTION 6: Accidental release measures**6.1 Personal precautions, protective equipment and emergency procedures**

- Personal precautions : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

- Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

- Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage**7.1 Precautions for safe handling**

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.

Etoricoxib Granulation Formulation

Version 3.6 Revision Date: 09.04.2021 SDS Number: 16722-00019 Date of last issue: 16.10.2020
Date of first issue: 29.09.2014

Local/Total ventilation : Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Advice on safe handling : Use only with adequate ventilation.
Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:
Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s) : No data available
No data available

SECTION 8: Exposure controls/personal protection**8.1 Control parameters****Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Cellulose	9004-34-6	TWA OEL-RL (Respirable dust)	5 mg/m ³	ZA OEL
Further information: Recommended Limit				
		TWA OEL-RL (inhalable dust)	10 mg/m ³	ZA OEL
Further information: Recommended Limit				
		STEL OEL-RL (Dust)	20 mg/m ³	ZA OEL
Further information: Recommended Limit				
Etoricoxib	202409-33-4	TWA	400 ug/m ³ (OEB 2)	Internal

Etoricoxib Granulation Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
3.6	09.04.2021	16722-00019	Date of first issue: 29.09.2014

8.2 Exposure controls**Engineering measures**

Ensure adequate ventilation, especially in confined areas.

Minimize workplace exposure concentrations.

Apply measures to prevent dust explosions.

Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment

Eye protection : Wear the following personal protective equipment:
Safety goggles

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Skin and body protection : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.
Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties**9.1 Information on basic physical and chemical properties**

Appearance : powder

Colour : No data available

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Etoricoxib Granulation Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
3.6	09.04.2021	16722-00019	Date of first issue: 29.09.2014

Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	1 g/cm ³
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, dynamic	:	No data available
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

9.2 Other information

Flammability (liquids)	:	No data available
Molecular weight	:	No data available
Particle size	:	No data available

SECTION 10: Stability and reactivity**10.1 Reactivity**

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
---------------------	---	--

10.4 Conditions to avoid

Etoricoxib Granulation Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
3.6	09.04.2021	16722-00019	Date of first issue: 29.09.2014

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information**11.1 Information on toxicological effects**

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg
Method: Calculation method

Components:**Etoricoxib:**

Acute oral toxicity : LD50 (Rat): 1.499 mg/kg
LD50 (Mouse): 1.499 mg/kg

Acute toxicity (other routes of administration) : LD50 (Rat): 238 mg/kg
Application Route: Intraperitoneal

LD50 (Mouse): 599 mg/kg
Application Route: Intraperitoneal

Skin corrosion/irritation

Not classified based on available information.

Components:**Etoricoxib:**

Species : Rabbit
Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Etoricoxib:**

Etoricoxib Granulation Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
3.6	09.04.2021	16722-00019	Date of first issue: 29.09.2014

Species : Rabbit
Result : Mild eye irritation

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Etoricoxib:**

Test Type : Local lymph node assay (LLNA)
Exposure routes : Skin contact
Species : Mouse
Assessment : Did not cause sensitisation on laboratory animals.
Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:**Etoricoxib:**

Genotoxicity in vitro : Test Type: reverse mutation assay
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: human lymphoblastoid cells
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: negative

Test Type: Alkaline elution assay
Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration
Species: Rat
Cell type: Bone marrow
Application Route: Oral
Result: negative

Test Type: Alkaline elution assay
Species: Rat
Application Route: Oral
Result: negative

Carcinogenicity

Not classified based on available information.

Etoricoxib Granulation Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
3.6	09.04.2021	16722-00019	Date of first issue: 29.09.2014

Components:**Etoricoxib:**

Species : Rat, male and female
 Application Route : oral (gavage)
 Exposure time : 2 Years
 Result : positive

Species : Mouse, male and female
 Application Route : oral (gavage)
 Exposure time : 2 Years
 Result : negative

Reproductive toxicity

Suspected of damaging the unborn child.

Components:**Etoricoxib:**

Effects on fertility : Test Type: Fertility/early embryonic development
 Species: Rat, female
 Application Route: Oral
 General Toxicity - Parent: NOAEL: 10 mg/kg body weight
 Result: positive

Test Type: Fertility/early embryonic development
 Species: Rat, male
 Application Route: Oral
 Result: negative

Effects on foetal development : Species: Rat
 Application Route: Oral
 Result: positive

Species: Rabbit
 Application Route: Oral
 Result: positive

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:**Etoricoxib:**

Exposure routes : Ingestion
 Target Organs : Kidney, Liver, Gastrointestinal tract
 Assessment : May cause damage to organs through prolonged or repeated exposure.

Etoricoxib Granulation Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
3.6	09.04.2021	16722-00019	Date of first issue: 29.09.2014

Repeated dose toxicity**Components:****Etoricoxib:**

Species	:	Rat
LOAEL	:	30 mg/kg
Application Route	:	oral (gavage)
Exposure time	:	27 Weeks
Target Organs	:	Gastrointestinal tract, Kidney

Species	:	Rat
NOAEL	:	30 mg/kg
Application Route	:	oral (gavage)
Exposure time	:	53 Weeks
Target Organs	:	Liver

Species	:	Dog
NOAEL	:	50 mg/kg
Application Route	:	oral (gavage)
Exposure time	:	53 Weeks
Target Organs	:	Liver

Species	:	Dog
LOAEL	:	200 mg/kg
Application Route	:	oral (gavage)
Exposure time	:	14 Weeks
Target Organs	:	Gastrointestinal tract, Kidney

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Etoricoxib:**

Ingestion	:	Symptoms: upper respiratory tract infection, Headache, hypertension, Diarrhoea, urinary tract infection, flu-like symptoms, heartburn, Nausea, bronchitis, Dizziness, asthenia, Rash, Back pain, Cough, Abdominal pain, pharyngitis, Oedema
-----------	---	---

SECTION 12: Ecological information**12.1 Toxicity****Components:****Etoricoxib:**

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 30 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 30 mg/l Exposure time: 48 h

Etoricoxib Granulation Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
3.6	09.04.2021	16722-00019	Date of first issue: 29.09.2014

		Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 10 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to microorganisms	:	EC50 : > 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
		NOEC : 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
Toxicity to fish (Chronic toxicity)	:	NOEC: 7,93 mg/l Exposure time: 32 d Species: Pimephales promelas (fathead minnow) Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC: 0,75 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

12.2 Persistence and degradability**Components:****Etoricoxib:**

Biodegradability	:	Result: not rapidly degradable Biodegradation: 0,2 % Exposure time: 28 d
------------------	---	--

12.3 Bioaccumulative potential**Components:****Etoricoxib:**

Partition coefficient: n-octanol/water	:	log Pow: 2,3
--	---	--------------

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment**Product:**

Assessment	:	This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
------------	---	--

Etoricoxib Granulation Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
3.6	09.04.2021	16722-00019	Date of first issue: 29.09.2014

12.6 Other adverse effects**Product:**

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations**13.1 Waste treatment methods**

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information**14.1 UN number**

ADN : UN 3077

ADR : UN 3077

RID : UN 3077

IMDG : UN 3077

IATA : UN 3077

14.2 UN proper shipping name

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Etoricoxib)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Etoricoxib)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Etoricoxib)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Etoricoxib)

IATA : Environmentally hazardous substance, solid, n.o.s.
(Etoricoxib)

14.3 Transport hazard class(es)

Etoricoxib Granulation Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
3.6	09.04.2021	16722-00019	Date of first issue: 29.09.2014

ADN	:	9
ADR	:	9
RID	:	9
IMDG	:	9
IATA	:	9

14.4 Packing group

ADN		
Packing group	:	III
Classification Code	:	M7
Hazard Identification Number	:	90
Labels	:	9
ADR		
Packing group	:	III
Classification Code	:	M7
Hazard Identification Number	:	90
Labels	:	9
Tunnel restriction code	:	(-)
RID		
Packing group	:	III
Classification Code	:	M7
Hazard Identification Number	:	90
Labels	:	9
IMDG		
Packing group	:	III
Labels	:	9
EmS Code	:	F-A, S-F

IATA (Cargo)		
Packing instruction (cargo aircraft)	:	956
Packing instruction (LQ)	:	Y956
Packing group	:	III
Labels	:	Miscellaneous

IATA (Passenger)		
Packing instruction (passenger aircraft)	:	956
Packing instruction (LQ)	:	Y956
Packing group	:	III
Labels	:	Miscellaneous

14.5 Environmental hazards

ADN		
Environmentally hazardous	:	yes
ADR		
Environmentally hazardous	:	yes
RID		
Environmentally hazardous	:	yes
IMDG		

Etoricoxib Granulation Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
3.6	09.04.2021	16722-00019	Date of first issue: 29.09.2014

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information**15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture**

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H302 : Harmful if swallowed.

H361d : Suspected of damaging the unborn child.

H373 : May cause damage to organs through prolonged or repeated exposure if swallowed.

H411 : Toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Chronic : Long-term (chronic) aquatic hazard

Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure

ZA OEL : South Africa. Hazardous Chemical Substances Regulations, Occupational Exposure Limits

ZA OEL / TWA OEL-RL : Long term occupational exposure limits - recommended limit

ZA OEL / STEL OEL-RL : Short term occupational exposure limits - recommended limit

Etoricoxib Granulation Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
3.6	09.04.2021	16722-00019	Date of first issue: 29.09.2014

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Repr. 2	H361d
STOT RE 2	H373
Aquatic Chronic 2	H411

Classification procedure:

Calculation method
Calculation method
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SAFETY DATA SHEET



Etoricoxib Granulation Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
3.6	09.04.2021	16722-00019	Date of first issue: 29.09.2014

ZA / EN